Labcorp Holdings, Inc. Q3 FY2026 earnings call

• Strong Financial Execution: Delivered 7% revenue growth, 14.5% EPS growth, and expanded adjusted operating margins by 60 basis points to 15%. Free cash flow reached $412 million.
• PAMA Headwinds: Management expressed disappointment with proposed Medicare fee schedule changes under PAMA, estimating a ~$125 million impact in 2027. They reaffirmed their long-term outlook but noted the need to offset these cuts through operational levers.
• Specialty Testing Leadership: Continued strong performance in specialty areas (oncology, neurology, women's health), growing three times faster than the broader market. Launched FDA-cleared Alzheimer’s test (PTAL 217) and advanced precision medicine capabilities via PGDX platform.
• Strategic Acquisitions & Partnerships: Completed acquisition of MLM Medical Labs to expand global central lab presence. Announced agreements to acquire BioReference Health assets, Myriad Genetics prenatal business, and Millennium Health. These deals are expected to be accretive to EPS in Year 1.
• Biopharma Laboratory Services (BLS): Robust demand in Central Lab Services (CLS) drove 11.3% organic constant currency growth. Backlog stands at $8.9 billion with a book-to-bill ratio of 1.13.
• Personalized Health Solutions: Launched consumer-focused tests including Advanced Health Panel and Marker by LabCorp Genetic Health Panel on LabCorp OnDemand.
• Technology & Innovation: Enhanced automation and digital pathology solutions; recognized by Forbes as an Best Employer for Tech Workers. Launched next-gen LabCorp Global Trial Connect.

• Diagnostics: Revenue of $2.9 billion, up 6.5% year-over-year (YoY). This segment accounted for approximately 76.3% of total enterprise revenue. Adjusted operating income was $492 million, representing a margin of 16.7%. Organic growth was 4.4%, driven by 3.1% volume growth and 1.3% favorable price mix.

• Full-Year 2026 Revenue: Raised midpoint by 50 basis points; expected growth of 5.9% to 6.7%.
• Full-Year 2026 EPS: Raised midpoint by $0.18; expected range of $18.30 to $18.70 (implied growth of 12.5%).
• Diagnostic Segment Growth: Raised midpoint by 20 basis points; expected growth of 5.5% to 6.2%.
• BLS Segment Growth: Raised midpoint by 190 basis points; expected growth of 7.4% to 8.4%. CLS expected to grow high single digits; Early Development low single digits.
• Margin Expansion: Anticipated enterprise margin expansion for FY2026 driven by diagnostics, BLS, and Launchpad productivity initiatives targeting $125 million in savings.
• Free Cash Flow: Maintained guidance range of $1.24 billion to $1.36 billion.
• 2027 Outlook: Estimated $125 million negative impact from PAMA in 2027; full 2027 guidance to be provided in February 2027.

• Regulatory/Reimbursement Risk: Significant headwind from proposed PAMA fee schedule changes, potentially reducing Medicare reimbursement rates for hundreds of tests starting 2027, threatening patient access and laboratory viability.
• Integration Risk: Execution risk associated with integrating multiple recent acquisitions (BioReference, Myriad, Millennium, MLM), particularly regarding timeline adherence and achieving projected synergies.
• Competitive Pressure: Need to maintain leadership in specialty testing against evolving clinical guidelines and competitor responses to payer friction.
• Capital Allocation: Balancing aggressive M&A pipeline with share repurchases ($1.4 billion remaining authorization) and dividends while maintaining debt levels ($5.9 billion total debt).

Q: How will margin progression be impacted by PAMA implementation and recent acquisitions in 2027? / A: Management expects continued margin expansion absent PAMA, utilizing four levers to offset the estimated $125 million hit: strong diagnostic volume, BLS strength, accelerated Launchpad efficiencies, and new business development. While exact 2027 guidance is deferred to February, they remain confident in moving into 2027 with momentum, noting that deal timings (e.g., Myriad in early 2027) will influence short-term margin profiles.